GlobeNewswire Inc.··NaSitryx's First-in-Class PKM2 Drug Clears Phase 1a, Eyes Atopic Dermatitis Market
Sitryx Therapeutics reports positive Phase 1a data for SYX-5219, a first-in-class oral PKM2 modulator showing safety and immunomodulation signals in atopic dermatitis development.
LLYGSKoral therapyclinical trial